Abstract: The present invention relates generally to compositions and methods for treating diseases and disorders caused by herpes simplex virus type 1, including herpes simplex keratitis, in a subject. In certain embodiments, the compositions of the present invention comprise an ATM inhibitor and an anti-herpetic agent. In other embodiments, the compositions comprise a Chk2 inhibitor and an anti-herpetic agent. In yet other embodiments, the compositions comprise a Chk2 inhibitor and an ATM inhibitor, and optionally an anti-herpetic agent.

Abstract: The present invention relates generally to compositions and methods for treating diseases and disorders caused by herpes simplex virus type 1, including herpes simplex keratitis, in a subject. In certain embodiments, the compositions of the present invention comprise an ATM inhibitor and an anti-herpetic agent. In other embodiments, the compositions comprise a Chk2 inhibitor and an anti-herpetic agent. In yet other embodiments, the compositions comprise a Chk2 inhibitor and an ATM inhibitor, and optionally an anti-herpetic agent.

Abstract: The present invention relates generally to compositions and methods for treating diseases and disorders caused by herpes simplex virus type 1, including herpes simplex keratitis, in a subject. In certain embodiments, the compositions of the present invention comprise an ATM inhibitor and an anti-herpetic agent. In other embodiments, the compositions comprise a Chk2 inhibitor and an anti-herpetic agent. In yet other embodiments, the compositions comprise a Chk2 inhibitor and an ATM inhibitor, and optionally an anti-herpetic agent.

Abstract: The present invention relates generally to compositions and methods for treating diseases and disorders caused by herpes simplex virus type 1, including herpes simplex keratitis, in a subject. In certain embodiments, the compositions of the present invention comprise an ATM inhibitor and an anti-herpetic agent. In other embodiments, the compositions comprise a Chk2 inhibitor and an anti-herpetic agent. In yet other embodiments, the compositions comprise a Chk2 inhibitor and an ATM inhibitor, and optionally an anti-herpetic agent.

Abstract: A method of constructing a wall is shown in which vertical structural columns are erected by mounting vertical, precast concrete panels to a vertical structural member located at each column foundation. The distance between two completed structural columns is spanned by sliding a precast, horizontal structural panel within a pair of column vertical recesses. The height of the horizontal panel is less than the total height of the structural columns and the remaining space is filled with a filler material which can assume a variety of shapes and configurations.

Abstract: A polysilicon layer or a single crystal silicon substrate is plasma etched in a two staged process. The first stage was a non-selective anisotropic etch to define a desired pattern by etching part way through the polysilicon. The second stage was a selective etch to secure remaining polysilicon and expose the substrate.

Abstract: A method of constructing a wall is shown in which vertical columns are erected by stacking a series of precast concrete elements. The elements are spaced-apart by temporary end members to define an upright passage within the column. Concrete is poured within the passage to fill the column interior. After the concrete hardens, the end members are removed to provide oppositely arranged, vertically extending recesses on the column exteriors. The distance between two completed columns is spanned by sliding a precast panel within two of the columns vertical recesses.